ZA200501477B - Use of PDE IV inhibitors to treat angiogenesis - Google Patents
Use of PDE IV inhibitors to treat angiogenesis Download PDFInfo
- Publication number
- ZA200501477B ZA200501477B ZA200501477A ZA200501477A ZA200501477B ZA 200501477 B ZA200501477 B ZA 200501477B ZA 200501477 A ZA200501477 A ZA 200501477A ZA 200501477 A ZA200501477 A ZA 200501477A ZA 200501477 B ZA200501477 B ZA 200501477B
- Authority
- ZA
- South Africa
- Prior art keywords
- pde
- inhibitors
- diabetic retinopathy
- edema
- inhibitor
- Prior art date
Links
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title claims description 15
- 230000033115 angiogenesis Effects 0.000 title description 15
- 206010029113 Neovascularisation Diseases 0.000 claims description 19
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 11
- 206010030113 Oedema Diseases 0.000 claims description 9
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 9
- 208000002780 macular degeneration Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002491 angiogenic effect Effects 0.000 claims description 5
- 210000001525 retina Anatomy 0.000 claims description 5
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 4
- KSPYMJJKQMWWNB-UHFFFAOYSA-N cipamfylline Chemical compound O=C1N(CC2CC2)C(=O)C=2NC(N)=NC=2N1CC1CC1 KSPYMJJKQMWWNB-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037765 diseases and disorders Diseases 0.000 claims description 2
- RQPOEGOXCVKURG-UHFFFAOYSA-N ethyl n-[4-[[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1CN1C(=O)CCC(C=2C=C(OC)C(OC)=CC=2)=N1 RQPOEGOXCVKURG-UHFFFAOYSA-N 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 229950002405 cipamfylline Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 10
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000964 angiostatic effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000002497 edematous effect Effects 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 201000000159 corneal neovascularization Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000002634 heparin fragment Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000649 photocoagulation Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 2
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000003142 neovascular glaucoma Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- AODPIQQILQLWGS-UHFFFAOYSA-N (3alpa,5beta,11beta,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one, Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 AODPIQQILQLWGS-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- TYNSUEXNGLNQSS-UHFFFAOYSA-N 6-carbamoyl-5-hydroxy-4-methoxy-7,8-dihydro-3h-pyrrolo[3,2-e]indole-2-carboxylic acid Chemical compound C1=2C=C(C(O)=O)NC=2C(OC)=C(O)C2=C1CCN2C(N)=O TYNSUEXNGLNQSS-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100025579 Calmodulin-2 Human genes 0.000 description 1
- 101710164734 Calmodulin-2 Proteins 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 208000024160 Fuchs heterochromic iridocyclitis Diseases 0.000 description 1
- 201000010479 Fuchs' heterochromic uveitis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044541 Traumatic shock Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960001232 anecortave Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000017 cortisol group Chemical group 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 230000004232 retinal microvasculature Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- -1 steroid compound Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41100102P | 2002-09-16 | 2002-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200501477B true ZA200501477B (en) | 2006-10-25 |
Family
ID=31994234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200501477A ZA200501477B (en) | 2002-09-16 | 2003-09-11 | Use of PDE IV inhibitors to treat angiogenesis |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20040053939A1 (fr) |
| EP (1) | EP1539174A4 (fr) |
| JP (1) | JP2006501269A (fr) |
| KR (1) | KR20050043923A (fr) |
| CN (1) | CN1681510A (fr) |
| AR (1) | AR041263A1 (fr) |
| AU (1) | AU2003267161A1 (fr) |
| BR (1) | BR0314364A (fr) |
| CA (1) | CA2497192A1 (fr) |
| MX (1) | MXPA05002146A (fr) |
| PL (1) | PL374659A1 (fr) |
| TW (1) | TW200412972A (fr) |
| WO (1) | WO2004024085A2 (fr) |
| ZA (1) | ZA200501477B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2851247B1 (fr) * | 2003-02-19 | 2007-06-29 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de pathologies degeneratives oculaires |
| JP2008500282A (ja) * | 2004-04-08 | 2008-01-10 | レットメッド ピーティーワイ リミテッド | 眼症状の治療 |
| KR20080065704A (ko) | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | 의학적 이상의 치료 방법들, 조성물들, 및 키트들 |
| PL2117524T3 (pl) * | 2007-01-29 | 2020-03-31 | National Research Council Of Canada | Zastosowanie katecholamin i pokrewnych związków jako środków przeciwangiogennych |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2570579B1 (fr) * | 1984-09-26 | 1987-01-09 | Salomon Sa | Dispositif de fermeture et de serrage d'une chaussure de ski a ouverture arriere |
| US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| GB9413975D0 (en) * | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
| US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| WO1998037894A1 (fr) * | 1997-02-28 | 1998-09-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Combinaison synergique d'inhibiteurs de la phosphodiesterase et d'agonistes de la cyclase d'adenylate ou d'agonistes de la cyclyse guanylique |
| US5866872A (en) * | 1997-07-25 | 1999-02-02 | Hypertherm, Inc. | Plasma arc torch position control |
| DE19812515A1 (de) * | 1998-03-21 | 1999-09-23 | M & F Entw & Patentverwertungs | Lamellenschleifwerkzeug |
| TR200100893T2 (tr) * | 1998-09-29 | 2001-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Piridopirazin bileşiğinin yeni tuzları ve bunların kristalleri |
| US6740664B2 (en) * | 1998-09-30 | 2004-05-25 | Alcon, Inc. | Methods for treating otic and ophthalmic infections |
| US6326888B1 (en) * | 1998-12-17 | 2001-12-04 | Ching-Yung Wang | Auxiliary safety warning light system for a vehicle |
| US6326388B1 (en) * | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
| AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
-
2003
- 2003-09-11 EP EP03749635A patent/EP1539174A4/fr not_active Ceased
- 2003-09-11 ZA ZA200501477A patent/ZA200501477B/en unknown
- 2003-09-11 WO PCT/US2003/028675 patent/WO2004024085A2/fr active Application Filing
- 2003-09-11 AU AU2003267161A patent/AU2003267161A1/en not_active Abandoned
- 2003-09-11 CN CNA038215454A patent/CN1681510A/zh active Pending
- 2003-09-11 MX MXPA05002146A patent/MXPA05002146A/es unknown
- 2003-09-11 JP JP2004536198A patent/JP2006501269A/ja active Pending
- 2003-09-11 US US10/660,152 patent/US20040053939A1/en not_active Abandoned
- 2003-09-11 PL PL03374659A patent/PL374659A1/xx not_active Application Discontinuation
- 2003-09-11 CA CA002497192A patent/CA2497192A1/fr not_active Abandoned
- 2003-09-11 KR KR1020057003469A patent/KR20050043923A/ko not_active Application Discontinuation
- 2003-09-11 BR BR0314364-3A patent/BR0314364A/pt not_active IP Right Cessation
- 2003-09-11 US US10/527,599 patent/US20060014782A1/en not_active Abandoned
- 2003-09-15 AR ARP030103340A patent/AR041263A1/es not_active Application Discontinuation
- 2003-09-15 TW TW092125341A patent/TW200412972A/zh unknown
-
2005
- 2005-08-16 US US11/204,938 patent/US20050277648A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200412972A (en) | 2004-08-01 |
| KR20050043923A (ko) | 2005-05-11 |
| US20040053939A1 (en) | 2004-03-18 |
| WO2004024085A3 (fr) | 2004-04-29 |
| CA2497192A1 (fr) | 2004-03-25 |
| JP2006501269A (ja) | 2006-01-12 |
| AR041263A1 (es) | 2005-05-11 |
| CN1681510A (zh) | 2005-10-12 |
| PL374659A1 (en) | 2005-10-31 |
| EP1539174A2 (fr) | 2005-06-15 |
| EP1539174A4 (fr) | 2006-10-25 |
| US20050277648A1 (en) | 2005-12-15 |
| US20060014782A1 (en) | 2006-01-19 |
| MXPA05002146A (es) | 2005-05-23 |
| AU2003267161A1 (en) | 2004-04-30 |
| BR0314364A (pt) | 2005-07-19 |
| WO2004024085A2 (fr) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Does laser still have a role in the management of retinal vascular and neovascular diseases? | |
| US20100048608A1 (en) | Histone Deacetylase Inhibitors for the Treatment of Ocular Neovascular or Edematous Disorders and Diseases | |
| JP2006512318A5 (fr) | ||
| JP2014198730A (ja) | 眼の疾患、ならびに増殖および脈管形成応答に関連する疾患の処置に関する５，６，７−トリヒドロキシヘプタン酸およびアナログ | |
| JP2007056041A (ja) | 病的な眼の新脈管形成を処置するための糖質コルチコイド処方物 | |
| US20050277648A1 (en) | Use of PDE IV inhibitors to treat angiogenesis | |
| Graber et al. | High intensity focused ultrasound cyclodestruction versus cyclodiode treatment of refractory glaucoma: a retrospective comparative study | |
| Pardines et al. | Bilateral choroidal effusion after selective laser trabeculoplasty | |
| US20040259765A1 (en) | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis | |
| JP2007500250A5 (fr) | ||
| EP2875811A1 (fr) | Utilisation de dobésilate pour le traitment d'hémorragie oculaire | |
| Findl | Redefining the treatment paradigm for post-operative inflammation control–the role of topical non-steroidal anti-inflammatory drugs | |
| ZA200509532B (en) | Formulations or non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis | |
| Cornish | Neovascular Glaucoma |